Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Abstract

BACKGROUND:

A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.

INVESTIGATIONS:

Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.

DIAGNOSIS:

Progressive neurofibromatosis-type-2-related vestibular schwannomas.

MANAGEMENT:

Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.

• Authors: Scott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, Gordon J Harris, Andrea I McClatchey, Chris Halpin
• Journal: Nature clinical practice. Oncology (Nat Clin Pract Oncol) Vol. 5 Issue 8 Pg. 487-91 (Aug 2008) ISSN: 1743-4262 [Electronic] England
• PMID: 18560388 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Protein Kinase Inhibitors
• Quinazolines
• Erlotinib Hydrochloride

Topics

• Audiometry, Pure-Tone
• Auditory Threshold
• Cochlear Implantation (methods)
• Combined Modality Therapy
• Ear Neoplasms (complications, drug therapy, surgery)
• Erlotinib Hydrochloride
• Hearing Loss, Sensorineural (diagnosis, etiology, prevention & control)
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Neurofibromatosis 2 (complications, drug therapy, surgery)
• Protein Kinase Inhibitors (administration & dosage)
• Quinazolines (administration & dosage)
• Treatment Outcome
• Vestibular Diseases (complications, drug therapy, surgery)